TANG Jiying 汤吉英
Vice President 副总裁
Chengdu Huasun Group Inc., Ltd. 成都华神集团股份有限公司
Bilateral Meetings
- Tuesday (09:00 am - 01:30 pm)
- Tuesday (14:00 pm - 17:00 pm)
DescriptionChengdu Huasun Group Inc., Ltd. [Stock code: 000790] is an industrial group, which base on modern Tcm and featured by its bio-pharmaceuticals, was listed in Shenzhen Stock Exchange in 1998. It has the world’s first monoclonal antibody RIA targeted drugs used in the treatment of primary hepatocellular carcinoma——Licartin (Iodine[131I] Metuximab monoclonal antibody Injection),Sanchi Tongshu Capsule,Biyuanshu oral liquid/capsule,Huolishu oral liquid and other products.
成都华神集团股份有限公司[股票代码:000790]于1998年在深交所挂牌上市,是一家以现代中药为核心、以生物制药为特色的健康医药产业集团。拥有全球首个用于原发性肝细胞肝癌治疗的单克隆抗体放射免疫靶向药物——利卡汀(碘[131I ]美妥昔单抗注射液)、三七通舒胶囊、鼻渊舒口服液\胶囊、活力苏口服液等产品。
Organization Type
Big Company / corporation,
CountryChina
CityChengdu, Hi-Tech Zone Google map
Areas of Activities
Health biotechnologies
Cooperate with European companies in pharmaceutical field, and Seek EU partners for clinical trial a
In order to achieve the globalization of Chinese medicinal product, our company plans to communicate and cooperate with European companies in pharmaceutical field, to jointly develop and register our product. In the next few years, the company also expects to find other cooperation partners in Europe, such as Contract research organization for clinical trial and distributors for prescription drugs etc.
为了实现中药产品的国际化,公司计划与医药领域的欧洲公司进行合作交流,共同进行产品的开发和注册。未来几年,公司还预计在欧洲范围内寻找其他的合作伙伴,例如临床试验相关的合作研究机构和处方药品分销商等。
Cooperation Offered
- Outsourcing co-operation
- Technical co-operation
- License agreement
- Manufacturing agreement
- Sales / Distribution
Cooperation Requested
- Outsourcing co-operation
- Technical co-operation
- License agreement
- Manufacturing agreement
- Sales / Distribution